US EditionEnrolment milestone met in CORCINCH-HF pivotal trial - Cardiovascular News
Summary by Cardiovascular News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Enrolment milestone met in CORCINCH-HF pivotal trial - Cardiovascular News
AccuCinch Ancora Heart has announced that it has reached the first enrolment milestone in the CORCINCH-HF pivotal trial evaluating the AccuCinch transcatheter left ventricular restoration system in patients with heart failure with reduced ejection fraction (HFrEF). Six-month follow-up data on these 250 patients will support the company’s premarket approval (PMA) submission to the US Food and Drug Administration (FDA). The AccuCinch system is an …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
